Expertise in
15
conditions

Dr. Mary Scholand

Pulmonary Medicine
1280 E Stringham Ave, 
Salt Lake City, UT 
On Staff At
Accepting New Patients
Expertise in
15
conditions
1280 E Stringham Ave, 
Salt Lake City, UT 

Overview

Mary Scholand is a Pulmonary Medicine provider in Salt Lake City, Utah. Dr. Scholand is highly rated in 15 conditions, according to our data. Her top areas of expertise are Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Lung Transplant. Dr. Scholand is currently accepting new patients.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in UT

Board Certifications

American Board Of Internal Medicine

Hospital Affiliations

University Of Utah Hospital And Clinics
Intermountain Health Layton Hospital
Mckay-Dee Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
PacificSource
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

Pulmonary Division - Sugarhouse
1280 E Stringham Ave, Salt Lake City, UT 84106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Enrollment Status: Completed
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drugs: Pirfenidone, Mycophenolate Mofetil
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug, Other
Study Drug: ND-L02-s0201
Study Phase: Phase 2
Pulmonary Fibrosis Foundation Patient Registry
Pulmonary Fibrosis Foundation Patient Registry
Enrollment Status: Completed
Publish Date: July 07, 2023
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: September 08, 2022
Intervention Type: Other, Drug
Study Drug: KD025
Study Phase: Phase 2
View 5 Less Clinical Trials

73 Total Publications

Baseline and Change in Peripheral Blood Transcriptome Enhance Outcome Prediction in Fibrotic Hypersensitivity Pneumonitis: A Prospective Multicenter Cohort Study.
Baseline and Change in Peripheral Blood Transcriptome Enhance Outcome Prediction in Fibrotic Hypersensitivity Pneumonitis: A Prospective Multicenter Cohort Study.
Journal: medRxiv : the preprint server for health sciences
Published: November 26, 2025
Similar Doctors
Nathan Dean
Expertise in
6
conditions
Dr. Nathan Dean
Pulmonary Medicine
Expertise in
6
conditions
Dr. Nathan Dean
Pulmonary Medicine

Int Critical Care

5121 S Cottonwood St, 
Murray, UT 
 (8.3 miles away)
801-507-7000
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philosophy of care statement/quote: I enjoygetting to know my patients as individuals andworking as partners to improve their healthI am originally from: Palo Alto, CaliforniaMy clinical interests are: Recurrent pneumonia,bronchiectasis, non-tuberculous mycobacteriaand other chronic lung infections. When not working, I enjoy: Family especially mygrandchildren, skiing including being a medicaladvisor to the Alta Ski Patrol, road cycling, hiking,backpacking, and travel to Mexico and Spain. Dr. Dean is highly rated in 6 conditions, according to our data. His top areas of expertise are Pneumonia, Hospital-Acquired Pneumonia, Bronchiectasis, and H1N1 Influenza.

Expertise in
6
conditions
Dr. Richard E. Kanner
Pulmonary Medicine
Expertise in
6
conditions
Dr. Richard E. Kanner
Pulmonary Medicine
50 N Medical Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-581-7806
Languages Spoken:
English
See accepted insurances

Richard Kanner is a Pulmonary Medicine provider in Salt Lake City, Utah. Dr. Kanner is highly rated in 6 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Cerebral Hypoxia, and Acute Interstitial Pneumonia.

Charles Elliott
Expertise in
2
conditions
Dr. Charles Elliott
Pulmonary Medicine
Expertise in
2
conditions
Dr. Charles Elliott
Pulmonary Medicine

Imed Physicians

5121 S Cottonwood St, 
Murray, UT 
 (8.3 miles away)
801-507-3380
Experience:
53+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pulmonary diseaseEmeritus Board Member Pulmonary Hypertension Association. Dr. Elliott is highly rated in 2 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension and Pulmonary Veno-Occlusive Disease.

Frequently Asked Questions about Dr. Mary Scholand

How do I make an appointment with Dr. Mary Scholand?

You can book an appointment with Dr. Mary Scholand by calling their office at 801-581-7806. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mary Scholand a top-rated expert for Interstitial Lung Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mary Scholand is classified as an Elite expert for Interstitial Lung Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mary Scholand specialize in?

While Dr. Mary Scholand is a Pulmonary Medicine, they have specific expertise in Interstitial Lung Disease, Acute Interstitial Pneumonia, and Pulmonary Fibrosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Mary Scholand participate in research or clinical trials?

Yes. Dr. Mary Scholand has published 73 articles and abstracts on conditions like Interstitial Lung Disease. You can view a list of Dr. Mary Scholand's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mary Scholand accept my insurance?

Dr. Mary Scholand accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 801-581-7806 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Scholand's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile